Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer
- PMID: 33229043
- DOI: 10.1016/j.ygyno.2020.11.003
Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer
Abstract
Objective: Germline genetic testing is crucial to the care of ovarian cancer patients, and as part of the guideline-based care for ovarian cancer patient's adherence to this recommendation has been low. We sought to determine whether embedding a genetic counselor (GC) within a medical and gynecologic oncology clinic would increase testing rates and improve the timeliness of testing.
Methods: Prospective cohort study of 358 ovarian cancer patients seen by medical and gynecologic oncologists between 2013 and 2015. Rates of referrals, completion of counseling, and genetic testing and timeliness of counseling were abstracted before and after a GC was embedded in the clinic in 2014. An additional year of data (2015) was collected to evaluate sustainability of the intervention.
Results: Between 2013 and 2015, 88-92% of women were referred for genetic testing, but in 2013 only 66% completed counseling and 61% were tested. After a GC was embedded in the clinic in 2014, more than 80% of referred women completed counseling and germline genetic testing. Time to genetic counseling also decreased from a median of 107 to 40 days, irrespective of age and cancer family history (p < 0.01).
Conclusions: Embedding a GC into the workflow for ovarian cancer patients is an effective way of improving access to genetic counseling, testing rates, and the timeliness of testing.
Keywords: Counselor; Genetic counseling; Genetic testing; Germline; Ovarian cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Dr. Judy E. Garber has the following COI: personal fees from Helix Genetics, Novartis Oncology, GTx, Aleta BioTherepeutics, H3 Biomedicine, Inc., Kronos Bio, American Society of Clinical Oncology (ASCO), James P. Wilmot Foundation, Inc., Diane Helis Henry Medical Research Foundation, and Adrienne Helis Melvin Medical Research Foundation, and other from Myriad Genetics, Astrazeneca, Ambry Genetics, Invitae Genetics, GV20 Therapeutics, American Association for Cancer Research, Breast Cancer Research Foundation, Konica Minolta, and Facing Our Risk of Cancer Empowered, outside the submitted work. Dr. Ursula Matulonis has the following COI: personal fees from Astrazeneca, Myriad Genetics, Clovis, Merck, Eli Lilly, Mersana, Geneos, Fuji Film, Cerulean, Immunogen, Novartis, and 2× Oncology, outside the submitted work. Ms. Kipnis reports personal fees from Invitae outside the submitted work. All other authors have nothing to disclose.
Similar articles
-
Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.Gynecol Oncol. 2020 Oct;159(1):221-228. doi: 10.1016/j.ygyno.2020.07.027. Epub 2020 Aug 7. Gynecol Oncol. 2020. PMID: 32778409
-
Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care.Gynecol Oncol. 2017 Oct;147(1):110-114. doi: 10.1016/j.ygyno.2017.07.141. Epub 2017 Aug 8. Gynecol Oncol. 2017. PMID: 28800943
-
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.Gynecol Oncol. 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19. Gynecol Oncol. 2021. PMID: 34023131 Free PMC article.
-
Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.Gynecol Oncol. 2019 Aug;154(2):379-382. doi: 10.1016/j.ygyno.2019.05.031. Epub 2019 Jun 10. Gynecol Oncol. 2019. PMID: 31196574 Free PMC article.
-
Hereditary breast-ovarian cancer: clinical findings and medical management.Plast Surg Nurs. 2007 Jul-Sep;27(3):124-7. doi: 10.1097/01.PSN.0000290280.48197.e7. Plast Surg Nurs. 2007. PMID: 17901820 Review.
Cited by
-
Stakeholders' views of integrating universal tumour screening and genetic testing for colorectal and endometrial cancer into routine oncology.Eur J Hum Genet. 2021 Nov;29(11):1634-1644. doi: 10.1038/s41431-021-00871-4. Epub 2021 Apr 2. Eur J Hum Genet. 2021. PMID: 33811254 Free PMC article.
-
Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.Breast Cancer Res Treat. 2023 Jul;200(1):63-72. doi: 10.1007/s10549-023-06870-x. Epub 2023 Mar 1. Breast Cancer Res Treat. 2023. PMID: 36856935 Free PMC article.
-
Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases.Breast Care (Basel). 2022 Apr;17(2):153-158. doi: 10.1159/000517021. Epub 2021 Jun 17. Breast Care (Basel). 2022. PMID: 35702497 Free PMC article.
-
The design, implementation, and effectiveness of intervention strategies aimed at improving genetic referral practices: a systematic review of the literature.Genet Med. 2021 Dec;23(12):2239-2249. doi: 10.1038/s41436-021-01272-0. Epub 2021 Aug 24. Genet Med. 2021. PMID: 34426665 Free PMC article.
-
The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient.Curr Oncol. 2023 May 1;30(5):4677-4687. doi: 10.3390/curroncol30050353. Curr Oncol. 2023. PMID: 37232811 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous